1 La salute e medicina di genere la ricerca sul campo focus su diabete e malattie croniche Genere e rischio cardiovascolare nel diabete. Giuseppe Seghieri Pistoia 7 giugno 2016, Ospedale San Jacopo _ Sala 2
2 Disclosure I have no actual or potential conflict of interest in relation to this presentation.
3 Percentage growth in age standardised diabetes prevalence, Peters SE et al, 2015
4 1. Does diabetes induce a more adverse cardiovascular disease (CVD) risk profile, and moreover are there differences in treatment of cardiovascular risk factors in diabetic women as compared to diabetic men? 2. Does diabetes induce a greater excess risk of adverse cardiovascular disease (CVD) in women, as compared to men and when does the risk-window open? 3. Does the hormonal milieu explain sex-gender differences in diabetes associated excess risk of CVD? 4. Does sex-gender matter in diabetic microangiopathy retinopathy and nephropathy? 5. Are there relevant sex-gender differences in drug therapy of diabetes?
5 Differences in mean blood pressure and lipids by diabetic status in women and men. The STRONG Study. Howard BV et al., Diabetes Care, 1998 Women Men
6 Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women s Heart Health Study S. G. Wannamethee, Diabetologia, 2012
7 Mean body mass index by age at diagnosis of type 2 diabetes for men and women aged between 30 and 90 years at diagnosis and with BMI >25 kg/m2 from the Scottish Care Information Diabetes Collaboration (SCI-DC) dataset. Peters SE et al. 2015
9 Odds of receiving treatment, if indicated, for women relative to men (A), and effectiveness of therapy on treatment (B) Diabetes Care 28: , 2005
10 Rossi MC, et al. Diabetes Care, 2013
11 1. Does diabetes induce a more adverse cardiovascular disease (CVD) risk profile, and moreover are there differences in treatment of cardiovascular risk factors in diabetic women as compared to diabetic men? 2. Does diabetes induce a greater excess risk of adverse cardiovascular disease (CVD) in women, as compared to men and when, in life, does the riskwindow open? 3. Does the hormonal milieu explain sex-gender differences in diabetes associated excess risk of CVD? 4. Does sex-gender matter in diabetic microangiopathy retinopathy and nephropathy? 5. Are there relevant sex-gender differences in drug therapy of diabetes?
12 Meta-analysis of three cohort studies demonstrating HRs of incident CAD, adjusted for traditional cardiovascular risk factors, in persons with versus without diabetes by sex. Kalyani RR, et al., Diabetes Care, 2014
13 Relative risk and women:men ratio of relative risks for coronary heart disease (CHD) and stroke in women and men with diabetes versus without diabetes. Peters SE et al., 2015
14 Incidence rate of first hospitalizations, expressed as events/person-years during the period 1 st January st December 2012 in Tuscany, for each cardiovascular disease Events No. Rate [(Events/1000person-yr (95% CI)] Males Females Males Females AMI No Diabetes 17,031 9, ( ) 1.25 ( ) Diabetes 3,708 2, ( ) 8.57 ( ) STROKE No Diabetes 16,573 15, ( ) 2.05 ( ) Diabetes 4,060 3, ( ) ( ) CHF No Diabetes 13,150 15, ( ) 1.95 ( ) Diabetes 4,072 4, ( ) ( ) LEA No Diabetes ( ) 0.09 ( ) Diabetes ( ) 1.32 ( ) MACE No Diabetes 44,865 38, ( ) 5.00 ( ) Diabetes 11,299 9, ( ) ( )
15 Relative risks for CVD women and men with diabetes versus without diabetes. T o t a l AMI N o. o f e v e n t s ; H R ( 9 5 % C I ) ; ( ) ; ( ) T o t a l CHF N o. o f e v e n t s ; H R ( 9 5 % C I ) ; ( ) ; ( ) ( ) > 8 5 y r ; ( ) ; ( ) y r ; ( ) ; ( ) y r ; ( ) ; ( ) y r ; ( ) ; ( ) y r ; ( ) ; ( ) y r ; ( ) > 8 5 y r y r y r y r y r y r ; ( ) ; ( ) ; ( ) ; ( ) ; ( ) ; ( ) ; ( ) ; ( ) ; ( ) ; ( ) 8 5 ; ( ) ; ( ) N o. o f e v e n t s ; H R ( 9 5 % C I ) T o t a l > 8 5 y r ; ( ) ; ( ) ; ( ) ; ( ) N o. o f e v e n t s ; H R ( 9 5 % C I ) ; ( ) T o t a l ; ( ) ; ( ) > 8 5 y r y r y r y r LEA ; ( ) ; ( ) ; ( ) ; ( ) ; ( ) ; ( ) y r y r y r Stroke ; ( ) ; ( ) ; ( ) ; ( ) ; ( ) ; ( ) ; ( ) y r 4 2 ; ( ) ; ( ) ; ( ) y r ; ( ) y r 2 4 ; ( ) 9 1 ; ( ) y r ; ( ) ; ( )
16 Relative risks for CVD women with diabetes vsersus men with diabetes. T o t a l > 8 5 y r AMI N o. o f e v e n t s ; H R ( 9 5 % C I ) ; ( ) ; ( ) T o t a l > 8 5 y r CHF N o. o f e v e n t s ; H R ( 9 5 % C I ) ; ( ) ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) N o. o f e v e n t s ; H R ( 9 5 % C I ) N o. o f e v e n t s ; H R ( 9 5 % C I ) T o t a l > 8 5 y r LEA ; ( ) ; ( ) T o t a l > 8 5 y r Stroke ; ( ) ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( ) y r ; ( )
17 Pooled women-to-men ratios of standardised mortality ratios (SMR) for incident coronary heart disease and stroke, and for mortality from cardiovascular disease, renal disease, cancer, and accident and suicide in people with type 1 diabetes Huxley RR et al., Lancet Diabetes Endocrinol, 2015
18 Multiple-adjusted women-to-men RRRs for any dementia, vascular dementia, and nonvascular dementia, comparing individuals with diabetes to those without diabetes. RRR between men and women for vascular dementia: 1.19 ( ) Chatterjee S et al. Diabetes Care, 2016
19 Possible causes of the high cardiovascular risk in women with diabetes Nutrition, Metabolism & Cardiovascular Diseases (2010) 20, 474e480
20 1. Does diabetes induce a more adverse cardiovascular disease (CVD) risk profile, and moreover are there differences in treatment of cardiovascular risk factors in diabetic women as compared to diabetic men? 2. Does diabetes induce a greater excess risk of adverse cardiovascular disease (CVD) in women, as compared to men? 3. Does the hormonal milieu explain sex-gender differences in diabetes associated excess risk of CVD? 4. Does sex-gender matter in diabetic microangiopathy retinopathy and nephropathy? 5. Are there relevant sex-gender differences in drug therapy of diabetes?
21 Benefits and Risks of the Two Hormone-Therapy Formulations Evaluated in the Women s Health Initiative during 5yr intervention period. NEJM, 2016
22 GPER= G protein-coupled estrogen receptor Meyer RM et al, Acta Physiol (Oxf), 2011.
23 1. Does diabetes induce a more adverse cardiovascular disease (CVD) risk profile, and moreover are there differences in treatment of cardiovascular risk factors in diabetic women as compared to diabetic men? 2. Does diabetes induce a greater excess risk of adverse cardiovascular disease (CVD) in women, as compared to men? 3. Does the hormonal milieu explain sex-gender differences in diabetes associated excess risk of CVD? 4. Does sex-gender matter in diabetic microangiopathy - retinopathy and nepropathy? 5. Are there relevant sex-gender differences in drug therapy of diabetes?
24 Sex-related differences in the cumulative risk of PR over 40 years of type 1 diabetes according to age of diabetes onset 0-4 yr 5-9 yr yr >15 yr Harjutsalo V et al., 2011
25 Gender differences in the incidence and progression of diabetic retinopathy among Japanese patients with type 2 diabetes mellitus: A clinic-based retrospective longitudinal study Kajiwara A et al., DRCP, 2014 Women Men
26 Sex-related differences in the cumulative risk of ESRD over 40 years of type 1 diabetes according to age of diabetes onset 0-4 yr 5-9 yr yr >15 yr Harjutsalo V et al., 2011
27 Independent correlates of nonalbuminuric and albuminuric renal impairment (egfr <60 ml/min per 1.73m 2, stage 3 CKD). The RIACE study. Penno G et al., J Hypertens, 2011
28 1. Does diabetes induce a more adverse cardiovascular disease (CVD) risk profile, and moreover are there differences in treatment of cardiovascular risk factors in diabetic women as compared to diabetic men? 2. Does diabetes induce a greater excess risk of adverse cardiovascular disease (CVD) in women, as compared to men? 3. Does the hormonal milieu explain sex-gender differences in diabetes associated excess risk of CVD? 4. Does sex-gender matter in diabetic microangiopathy retinopathy and nephropathy? 5. Are there relevant sex-gender differences in drug therapy of diabetes?
30 Sex Differences in CVD Treatments and Interventions in DM
32 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013:
33 Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes The EMPA-REG trial (Zinman B et al.; NEJM, 2015) Placebo: Women : 30% Empagliflozin: Women: 29%
34 CONCLUSIONS Diabetes induces a more adverse cardiovascular disease (CVD) risk profile in women, combined with major differences in treatment of risk factors between men and women. Diabetes induces a greater excess risk of adverse cardiovascular disease (CVD) in women, as compared to men, in both type 1 and type 2, and this risk excess increases significantly in postmenopausal period. A different hormonal milieu may be important in yielding different outcomes in women, when compared to men. In type 1 diabetes the risk of microangiopathy (nephropathy and retinopathy) is significantly different between sexes, according to age of onset. There is the suggestion of a sexual dimorphism in the risk of albuminuric and non-albuminuric ESRD in type 2 diabetes.
35 CONCLUSIONS (cont d) There are substantial sex-gender differences in drug therapy of patients with diabetes: Women are more prone to have side effects after MET therapy, have different therapeutic outcomes after therapy with GLP-1 RA, have a significant risk excess of CHD after longstanding therapy with SUs and finally continue to be hugely underrepresented in CRT concerning cardiovascular benefits from medication with novel antidiabetic drugs. Further clarification and understanding of the mechanisms responsible for sex gender differences in the excess risk of complications associated with diabetes will be needed to improve and personalize the prevention and management of diabetes in clinical practise, in the global effort of reduce the rate of its hominous outcomes.
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS - Summary CHRONIC COMPLICATIONS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS - Epidemiological study - PhD Manager: Professor PhD.
Aspirin in CKD and in Diabetes Alberto Zanchetti, Centro di Fisiologia Clinica e Ipertensione, Università di Milano Istituto Auxologico Italiano, Milano (Italia) Questions 1. Does aspirin reduce CVD outcomes
Cholesterol Treatment Trialists (CTT) Collaboration Slide deck CTT Collaboration: Background* History: Founded in 1993 (prior to publication of 4S trial in 1994) Original protocol published in 1995 Trial
Prevention of Cardiovascular Disease in Children with Diabetes Stephen R. Daniels, MD, PhD Department of Pediatrics University of Colorado School of Medicine The Children s Hospital Anschutz Medical Campus
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
Chronic Kidney Disease: Proposed Revisions to the ICD-9-CM Classification Lesley Stevens MD Tufts-New England Medical Center National Kidney Foundation Objectives Kidney Failure Stages of Chronic Kidney
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
CHRONIC KIDNEY DISEASE PRACTICE GUIDELINES Reviewed and approved 5/2014 Risk Chronic kidney disease is defined as either kidney damage or decreased kidney function (decreased GFR) for 3 or more months.
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
Cardiovascular risk calculator for diabetic patients 이해영서울대학병원순환기내과 Contents Need of risk engine for diabetic patients Three main approaches of global cardiovascular risk estimation in diabetes Validation
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
Goals of This Course Be able to understand a study design (very basic concept) Be able to understand statistical concepts in a medical paper Be able to perform a data analysis Understanding: PECO study
Shaping the Future of the Dialysis Industry Payment Structure Implications for Integrated Disease Management and Bundled Payment Approach Robert Farrell Capital Markets Day September 20-21, 2007 Agenda
Safety of New Antihyperglycemics in Patients with Cardiovascular Disease Lori MacCallum, BScPhm, PharmD, RPh, CDE Assistant Professor, Leslie Dan Faculty of Pharmacy Sun Life Financial Professor in Wellness
School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney The evidence Life expectancy reduced by
Mortality and metabolic disorder in schizophrenia and bipolar disorder in Sweden, Denmark and Finland Urban Ösby Karolinska Institutet, Stockholm, Sweden Department of Psychiatry, Tiohundra AB, Norrtälje
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
DIABETES FACT SHEET IN KOREA 2013 DIABETES FACT SHEET IN KOREA 2013 SUMMARY Among adults aged 30 years and older, about 4 million Koreans (12.4%) had diabetes in 2011. 20% of Korean adults were diagnosed
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
Recent and Ongoing Cardiovascular Outcomes Trials with Diabetes Drugs Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller
AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division
Title Oral health conditions and medical complications of type 2 diabetics Author(s) Lee, RCY; Siu, SC; Leung, WK; Chu, FCS; Wong, CKW Citation The 19th Annual Scientific Meeting of the International Association
Diabetes and cardiovascular risk: MIND.IT Study The clinical reality of guidelines for primary prevention of cardiovascular disease in type 2 diabetes in Italy Prof. Ivana Zavaroni Dipartimento di Medicina
Appendix: Description of the DIETRON model Much of the description of the DIETRON model that appears in this appendix is taken from an earlier publication outlining the development of the model (Scarborough
Mortality Associated with Diabetes A review paper prepared for the 7th Global Conference of Actuaries, New Delhi, 15-16 February, 2005 Dr. David Muiry, MB;BS, FIA, FASI David_Muiry@swissre.com Introduction
The role of a low sodium diet in the management of hypertension Dave Glover Consultant Nephrologist, Wrexham Salt Aims Is it all a bit Woman s Own / Daily Mail? Current guidelines An idea about salt What
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
Therapeutic Inertia Dr Samuel Seidu. Declaration of interests Sam Seidu has acted as advisory board member and/or speaker for Novartis, Janssen, Novo Nordisk, Lilly, Boehringer Ingelheim, MSD, Amgen, Astra
ASCVD Risk Calculators, Controversies and Women Ann Cannon, RN, BSN Clinical Specialist for Cardiovascular Health and Heart Failure, MaineHealth Nurse Care Manager, Turning Point Heart Health Program Maine
1 NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Guideline title SCOPE Hypertension: clinical management of primary hypertension in adults 1.1 Short title Hypertension (partial update) 2 The remit
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke
Quick reference guide for health professionals Absolute cardiovascular disease risk assessment This quick reference guide is a summary of the key steps involved in assessing absolute cardiovascular risk
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke
With Big Data Comes Big Responsibility Using health care data to emulate randomized trials when randomized trials are not available Miguel A. Hernán Departments of Epidemiology and Biostatistics Harvard
Hypertension a timeless problem with new frontiers A. Oussama Rifai, MD Vice President of Medical Affairs The Virtual Nephrologist, Inc. Hypertension at a glance The number one modifiable risk factor for
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
Randomized trials versus observational studies The case of postmenopausal hormone therapy and heart disease Miguel Hernán Harvard School of Public Health www.hsph.harvard.edu/causal Joint work with James
Review of Diabetes Therapies: Key Drivers of Disease Progression David M. Kendall, MD Medical Director and Chief of Clinical and Professional Services Associate Professor of Medicine University of Minnesota
CKD Model Technical Document This report arises from the project EConDA which has received funding from the European Union in the framework of the Health Programme. Project number: 2012 12 13 Introduction
1. 2. RAW PREVALENCE FOR NORTHERN IRELAND AS AT 31 MARCH 214 3.1 Coronary Heart Disease (CHD) 3.2 Heart Failure 1 3.3 Heart Failure 3 (heart failure due to Left Ventricular Systolic Dysfunction) 3.4 Stroke
Chapter 20 Diabetes Mellitus Chapter 20 Lesson 20.1 Key Concept Diabetes mellitus is a metabolic disorder of glucose metabolism with many causes and forms. About Diabetes 20.8 million Americans have diabetes
DIABETES WEIGHT ENDOBARRIER THERAPY The first endoscopically-delivered device therapy for obese patients with type 2 diabetes Restore the metabolic health of your patients with EndoBarrier Therapy. Dual
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What
Launch of the MOH Clinical Practice Guidelines on Screening for Cardiovascular Disease and Risk Factors 23rd April 2011 Global Risk Assessment Dr Low Lip Ping Low Cardiology Clinic Global Risk Assessment
Type 2 Diabetes Media Fact Sheet 1. Type 2 diabetes: Facts & figures 2. What is type 2 diabetes? 3. Risk factors for type 2 diabetes 4. Complications associated with type 2 diabetes 5. The socio-economic
Antiplatelet drugs for the treatment and prevention of vascular disease: A review of recent clinical trials Niteesh K. Choudhry, MD, PhD Nihar Desai, MD, MPH Michael Fischer, MD, MS Jerry Avorn, MD Eimir
EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA A CASE STUDY EXAMINING RISK FACTORS AND COSTS OF UNCONTROLLED HYPERTENSION ISPOR 2013 WORKSHOP
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
Hormone therapy and breast cancer: conflicting evidence Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group The world of hormone therapy in the 1990 s Throughout the 1970s, 1980s and 1990s
Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, 2011 - ESRD Registry Committee, Korean Society of Nephrology* =Abstracts= Registry committee of Korean Society of Nephrology
ASCVD Risk Assessment in Pre and Post menopausal Women: Is it All About Age? National Lipid Association 2016 New Orleans, LA 22 May 2016 Martha Gulati, MD, MD, FACC, FAHA Professor of Medicine, Division
SUPPLEMENTAL MATERIAL Table S1. The logistic regression model used to calculate the propensity score. Table S2. Distribution of propensity score among the treat and control groups of the full and matched
DIABETES 25 OH Vitamin D TOTAL Assay 25-hydroxyvitamin D: from bone and mineral to general health marker FOR OUTSIDE THE US AND CANADA ONLY Vitamin D Receptors Brain Heart Breast Colon Pancreas Prostate
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
Stat1600 Solution to Midterm #2 Form A 1. (10 points) According to the Centers for Disease Control and Prevention, 33.5% U.S. adults have high LDL, or bad, cholestrol. Given a random sample of n=12 U.S.
Key Components of the Research Question PICOT CONTEXT: Low birth weight is implicated as a risk factor for type 2 diabetes. However, the strength, consistency, independence, and shape of the association
New-Onset Diabetes after Transplantation Dr Mahmoud Darouich Ministry of Health - Damascus The tenth conference of syrian society of nephrology and transplantation Mashta-Alhelou 6-8/11/2008 Cause of Death
Diabetes Mellitus: A Collaborative Approach to Management Ira B. Lamster, D.D.S., M.M.Sc. Joshua S. Coren, D.O., MBA, FACOFP Learning Objectives Implement collaboration strategies within respective practice
Measure #128 (NQF 0421): Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan National Quality Strategy Domain: Community/Population Health 2015 PQRS OPTIONS F INDIVIDUAL MEASURES:
Combined Diet and Physical Activity Promotion s to Prevent Type 2 Diabetes Among People at Increased Risk Results of Comparative Studies of Combined Diet & Physical Activity vs. Categorical Outcomes Author,
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
Hormone Replacement Therapy : The New Debate Susan T. Hingle, M.D. Background Hormone replacement therapy (HRT) is extensively used in the United States, especially for: *treatment of menopausal symptoms
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
Anti-Aging Aging g Medications What is the Evidence? Sixth Annual Family Medicine Conference Crown Plaza November 11, 2007 Presented by : Jad J. Sakr, Pharm.D. Outline Introduction Oidti Oxidative damage
KEY FACTS Diabetes is on the rise, and is among the top 10 causes of death in Singapore. Indians are most likely to have diabetes, followed by the Malays and Chinese. The risk of diabetes can be reduced
4 MORTALITY Bridget Robson, Gordon Purdie Key points There were 2,650 deaths a year on average among Màori during 2000 2004. A third occurred in middle age (45 64 years) and 40% among those aged 65 years
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
South African Cholesterol Guidelines Compared Jacqueline van Schoor, Amayeza Info Centre While infectious diseases are currently the leading cause of death in South Africa, cardiovascular disease (CVD)
Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität